CR9481A - MIMETICBODIES OF SIMILAR PEPTIDE TO GLUCAGON-1 HUMANS, COMPOSITIONS, METHODS AND USES - Google Patents

MIMETICBODIES OF SIMILAR PEPTIDE TO GLUCAGON-1 HUMANS, COMPOSITIONS, METHODS AND USES

Info

Publication number
CR9481A
CR9481A CR9481A CR9481A CR9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
mimeticbodies
glucagon
humans
Prior art date
Application number
CR9481A
Other languages
Spanish (es)
Inventor
T O'neil Karyn
Picha Kristen
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CR9481A publication Critical patent/CR9481A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere por lo menos un mimeticuerpo de GLP-1 humano novedoso o porcion o variante especificada, que incluye acidos nucleicos aislados que codifican por lo menos un mimeticuerpo de GLP-1 o porcion o variante especificada, mimeticuerpo de GLP-1 o porcion o variante especificadas, vectores, celulas hospedero, animales transgenicos o plantas, y metodos para hacer y usar los mismos, incluyendo composiciones terapeuticas, metodos y dispositivos.The present invention relates to at least one novel human GLP-1 mimicibody or specified portion or variant, which includes isolated nucleic acids encoding at least one GLP-1 mimicport or specified portion or variant, GLP-1 mimicibody or specified portion or variant, vectors, host cells, transgenic animals or plants, and methods for making and using them, including therapeutic compositions, methods and devices.

CR9481A 2005-03-28 2007-10-29 MIMETICBODIES OF SIMILAR PEPTIDE TO GLUCAGON-1 HUMANS, COMPOSITIONS, METHODS AND USES CR9481A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28

Publications (1)

Publication Number Publication Date
CR9481A true CR9481A (en) 2009-01-14

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9481A CR9481A (en) 2005-03-28 2007-10-29 MIMETICBODIES OF SIMILAR PEPTIDE TO GLUCAGON-1 HUMANS, COMPOSITIONS, METHODS AND USES

Country Status (12)

Country Link
EP (1) EP1871811A4 (en)
JP (1) JP2008546373A (en)
KR (1) KR20080005378A (en)
CN (1) CN101389346A (en)
AU (1) AU2005339797A1 (en)
BR (1) BRPI0520168A2 (en)
CA (1) CA2603359A1 (en)
CR (1) CR9481A (en)
IL (1) IL186307A0 (en)
MX (1) MX2007011975A (en)
NO (1) NO20075272L (en)
WO (1) WO2007081302A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30820A1 (en) 2006-12-21 2008-07-03 Centocor Inc USE OF LONG-TERM ACTION GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES
CN111574583B (en) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 Protein renaturation reagent and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3224700A (en) * 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
KR20080085082A (en) * 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Glp-1 fusion proteins
EP1545608A4 (en) * 2002-06-28 2006-09-13 Centocor Inc Mammalian ch1 deleted mimetibodies, compositions, methods and uses
CA2490411A1 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
JP2008537873A (en) * 2004-03-31 2008-10-02 セントカー・インコーポレーテツド Human GLP-1 mimetibody, compositions, methods and uses

Also Published As

Publication number Publication date
WO2007081302A3 (en) 2008-11-13
IL186307A0 (en) 2008-01-20
CN101389346A (en) 2009-03-18
EP1871811A2 (en) 2008-01-02
JP2008546373A (en) 2008-12-25
BRPI0520168A2 (en) 2009-04-22
EP1871811A4 (en) 2009-07-22
AU2005339797A1 (en) 2007-07-19
MX2007011975A (en) 2008-03-14
KR20080005378A (en) 2008-01-11
NO20075272L (en) 2007-12-28
CA2603359A1 (en) 2007-07-19
WO2007081302A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
UY30494A1 (en) MIMETICBODIES OF GLP-1 HUMANS, COMPOSITIONS, METHODS AND USES
AR049014A1 (en) MIMETICBODIES OF GLP-1 HUMANS, COMPOSITIONS AND USES
CR8320A (en) CENTRAL HUMAN MIMETRIC BODIES OF THE HINGE REGION, ERYTHROPOYETINE MIMETICS, COMPOSITIONS, METHODS AND USES
CR9606A (en) ANTI-PROTEIN QUINOATRAYENTE ANTIBODIES OF MONOCITS-1, COMPOSITIONS, METHODS AND USES
NI200700158A (en) GLP-1 AGONISTS, COMPOSITIONS, METHODS AND USES
NI201000056A (en) ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES.
HN2006016512A (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
CR9443A (en) C. PERFRINGENS ALFA TOXOID VACCINE
UY28757A1 (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
CR9514A (en) NPY ANTAGONISTS, PREPARATION AND USES
UY30820A1 (en) USE OF LONG-TERM ACTION GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES
PE20220960A1 (en) PROTEINS OF VARIANTS OF AMINO ACID SEQUENCES OF CRY1DA1 ACTIVE FOR LEPIDOPTERA
NO20055612L (en) Anti-inflammatory phosphonate compounds
CR9481A (en) MIMETICBODIES OF SIMILAR PEPTIDE TO GLUCAGON-1 HUMANS, COMPOSITIONS, METHODS AND USES
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
DOP2006000117A (en) INTERFERON-BETA GENE THERAPY USING AN IMPROVED REGULATED EXPRESSION SYSTEM
UY27973A1 (en) DEBENCENOXAZEPINAS
ES2337005R (en) PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICATIONS.
CL2007003811A1 (en) NON-NATURAL PROTEASE INHIBITORS OF THE KUNITZ TYPE THAT HAVE AMONG 56-60 AMINO ACIDS; NUCLEIC ACID CODING A NON-NATURAL PROTEASA INHIBITOR; USE OF SUCH INHIBITOR FOR TREATMENT OF HEMORRAGIES.
AR030133A1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
UY29552A1 (en) ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
DOP2003000696A (en) DEBENCENOXAZEPINAS
UY29509A1 (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
ECSP066764A (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
AR030135A1 (en) ANTI-DUAL INTEGRINE ANTIBODIES, COMPOSITIONS, METHODS AND USES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)